Lineage Cell Therapeutics, Inc. (LCTX)
LCTX moved a median of +0.07% 30 minutes after news, and -0.95% by the close. How LCTX actually reacts to news — the realized, point-in-time move the market made, measured across 75 labeled events over the last three years with zero look-ahead.
LCTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.45% | 57% | 75 |
| 30-min | +0.07% | 51% | 75 |
| 60-min | 0.00% | 48% | 75 |
| to close | -0.95% | 39% | 75 |
| Middle 50% of LCTX reactions | -1.55% to +1.73% |
|---|---|
| Median reaction (30-min) | +0.07% |
| Measured reactions | 75 |
Half of all Lineage Cell Therapeutics, Inc. news events land between -1.55% and +1.73% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when LCTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to LCTX's baseline. Nothing else.
Recent LCTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform | Press release | Business Wire | +2.73% | -0.91% | |
| Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | Business Wire | +2.27% | +0.00% | |
| Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 | Press release | Business Wire | -0.09% | +4.72% | |
| Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease | Press release | Business Wire | +0.80% | -3.20% | |
| Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit | Press release | Business Wire | +0.37% | -2.21% | |
| Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets | Press release | Canada Newswire | +0.00% | +5.74% | |
| Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | Business Wire | -4.85% | -4.48% | |
| Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026 | Press release | Business Wire | +1.03% | +0.00% | |
| OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026 | Press release | Business Wire | +0.67% | -5.33% | |
| Lineage Announces Formation of Scientific Advisory Board | Press release | Business Wire | +2.06% | +3.42% | |
| Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease | Press release | Business Wire | -0.69% | +2.07% | |
| Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Press release | Business Wire | -1.29% | -4.64% | |
| Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026 | Press release | Business Wire | +1.05% | +3.16% | |
| Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience | Press release | Business Wire | +0.30% | +1.80% | |
| Lineage Cell Therapeutics Issues Letter to Stockholders | Press release | Business Wire | +0.92% | +3.05% | |
| Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy | Press release | PR Newswire | +0.00% | +3.75% | |
| Dimension Bio Announces Inaugural Clinical and Scientific Advisory Boards | Press release | PR Web | +1.67% | +7.22% | |
| Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | Business Wire | +4.14% | +12.10% | |
| Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025 | Press release | Business Wire | +0.60% | +10.18% | |
| Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes | Press release | Business Wire | -0.20% | -0.80% | |
| Lineage Cell Therapeutics to Present at September 2025 Investor Conferences | Press release | Business Wire | +0.42% | +1.67% | |
| Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss | Press release | Business Wire | +2.40% | +0.00% | |
| Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | Business Wire | +2.06% | +6.19% | |
| Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025 | Press release | Business Wire | +0.85% | -1.41% | |
| Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury | Press release | Business Wire | +2.00% | -3.00% | |
| OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025 | Press release | Business Wire | -2.86% | -3.09% | |
| Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium | Press release | Business Wire | +1.33% | -0.48% | |
| Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC | Press release | Business Wire | +0.77% | -2.55% | |
| Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | Business Wire | +0.77% | -2.55% | |
| RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025 | Press release | Business Wire | -2.10% | +0.86% | |
| Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 | Press release | Business Wire | -4.12% | +1.74% | |
| Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium | Press release | Business Wire | -0.66% | +5.27% | |
| Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO) | Press release | Business Wire | -2.19% | -3.78% | |
| Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | Press release | Business Wire | -4.11% | -1.31% | |
| Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025 | Press release | Business Wire | +1.13% | -2.52% | |
| Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury | Press release | Business Wire | -2.46% | -1.86% | |
| Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference | Press release | Business Wire | -1.10% | -4.31% | |
| Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering | Press release | Business Wire | -1.56% | -0.02% | |
| Lineage Cell Therapeutics Issues Letter to Stockholders | Press release | Business Wire | -0.36% | -9.05% | |
| Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering | Press release | Business Wire | -2.63% | -18.73% | |
| Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering | Press release | Business Wire | -2.85% | -12.97% | |
| Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update | Press release | Business Wire | +0.03% | -7.70% | |
| Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024 | Press release | Business Wire | +2.77% | +0.57% | |
| Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit | Press release | Business Wire | +0.00% | +1.06% | |
| OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium | Press release | Business Wire | +0.92% | -1.76% | |
| Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop | Press release | Business Wire | +0.45% | -3.92% | |
| Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference | Press release | Business Wire | +0.37% | -2.11% | |
| Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update | Press release | Business Wire | +1.76% | -1.23% | |
| Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 | Press release | Business Wire | +0.00% | -6.40% | |
| Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index | Press release | Business Wire | +1.04% | -1.88% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the LCTX section they belong to.
Where else LCTX is measured.
LCTX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Lineage Cell Therapeutics, Inc.'s median reaction calculated?
Every labeled LCTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 75 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of LCTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does LCTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.